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Abstract
Background: The dioxin (AhR) receptor can have oncogenic or tumor suppressor activities depending on the
phenotype of the target cell. We have shown that AhR knockdown promotes melanoma primary tumorigenesis
and lung metastasis in the mouse and that human metastatic melanomas had reduced AhR levels with respect to
benign nevi.
Methods: Mouse melanoma B16F10 cells were engineered by retroviral transduction to stably downregulate AhR
expression, Aldh1a1 expression or both. They were characterized for Aldh1a1 activity, stem cell markers and
migration and invasion in vitro. Their tumorigenicity in vivo was analyzed using xenografts and lung metastasis
assays as well as in vivo imaging.
Results: Depletion of aldehyde dehydrogenase 1a1 (Aldh1a1) impairs the pro-tumorigenic and pro-metastatic
advantage of melanoma cells lacking AhR expression (sh-AhR). Thus, Aldh1a1 knockdown in sh-AhR cells
(sh-AhR + sh-Aldh1a1) diminished their migration and invasion potentials and blocked tumor growth and
metastasis to the lungs in immunocompetent AhR+/+ recipient mice. However, Aldh1a1 downmodulation in
AhR-expressing B16F10 cells did not significantly affect tumor growth in vivo. Aldh1a1 knockdown reduced the
high levels of CD133+/CD29+/CD44+ cells, melanosphere size and the expression of the pluripotency marker Sox2
in sh-AhR cells. Interestingly, Sox2 increased Aldh1a1 expression in sh-AhR but not in sh-AhR + sh-Aldh1a1 cells,
suggesting that Aldh1a1 and Sox2 may be co-regulated in melanoma cells. In vivo imaging revealed that mice
inoculated with AhR + Aldh1a1 knockdown cells had reduced tumor burden and enhanced survival than those
receiving Aldh1a1-expressing sh-AhR cells.
Conclusions: Aldh1a1 overactivation in an AhR-deficient background enhances melanoma progression. Since AhR
may antagonize the protumoral effects of Aldh1a1, the AhRlow-Aldh1a1high phenotype could be indicative of bad
outcome in melanoma.
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Background
Melanomas are steedely increasing in the human popula-
tion often resulting in a metastatic disease with poor pa-
tient survival [1, 2]. Despite the adverse prognosis of
melanoma, only a small number of molecular markers
including activating mutations in the B-RAF [3] and
Melan-A/MART1 [4, 5] genes have been suggested as po-
tentially relevant for the clinic. Aldehyde dehydrogenases
(Aldh) are enzymes responsible for intracellular aldehyde
metabolism [6] that have gained recent interest as poten-
tial diagnostic markers in melanoma. The Aldh1a1 iso-
form, which metabolizes retinal to retinoic acid, appears
particularly important because of its ability to regulate
melanogenesis [7]. Aldh1a1 has been associated to the
cancer stem/tumor initiating cell phenotype in human
sarcomas [8], nasopharylgeal carcinomas [9], breast car-
cinomas [10] and melanoma [11–13], and its level of ex-
pression and/or activity could represent a potential tool to
identify stem-like cells in melanoma tumors [11, 14]. In
vivo xenografts of Aldh1a1high human melanoma cells in
immunodeficient nude [15, 16], NGS [11] or NOD/SCID
[12] mice produced larger a more aggressive tumors, sug-
gesting that Aldh1a1 activity favoured tumorigenesis.
Nevertheless, the molecular mechanisms by which
Aldh1a1 influences melanoma progression are mostly
unknown.
The dioxin receptor (AhR) integrates signaling path-
ways controlling not only xenobiotic metabolism but
also tissue and organ homeostasis [17]. AhR expression
has opposite roles in tumor progression increasing the
growth of liver [18] and stomach tumors [19] while
inhibiting intestinal carcinogenesis [20] in mice. In
addition, AhR blocked the epithelial-to-mesenchymal
transition (EMT) associated to tumor invasion [21] and
its levels were reduced by promoter hypermethylation in
acute lymphoblastic leukemia cells [22].
AhR has a role in melanoma primary tumorigenesis
and lung metastasis. Indeed, we have recently reported
that stable AhR knockdown in B16F10 melanoma cells
enhanced their tumorigenicity and their metastatic po-
tential to the lungs whereas constitutive AhR activation
strongly blocked melanoma progression. AhR knock-
down increased melanoma cell migration and invasion
and the expression of mesenchymal markers α-smooth
muscle actin and Snail. Interestingly, the pro-tumoral
phenotype caused by AhR depletion in the tumor cell
required AhR expression in the microenvironment as
AhR−/− mice could not support tumor growth and
metastatization of melanoma cells interfered for AhR
[23]. The cell-autonomous effects of AhR depletion
appeared to involve an EMT process and an increased
content of cancer stem-like cells. Consistently, human
melanoma cells and biopsies from melanoma patients
had reduced AhR expression as compared to bening nevi
[23]. Nevertheless, the molecular intermediates regulat-
ing the protumoral effects of AhR deficiency could not
be determined.
In this study, we have found that Aldh1a1 upregula-
tion is likely an intermediate factor promoting melan-
oma growth and metastasis in AhR depleted cells.
Consistent with that hypothesis, AhR knockdown failed
to exert a pro-tumoral effect when Aldh1a1 was simul-
taneously inactivated. Interestingly, depletion of basal
Aldh1a1 levels in AhR-expressing melanoma cells did
not significantly affect tumor growth, suggesting that the
overactivation of Aldh1a1 is likely a causal factor
increasing the tumorigenicity of AhR deficient melan-
oma cells. Therefore, the tumor suppresor role of AhR
in melanoma [23] could take place by antagonizing the
Aldh1a1 activity. We suggest that the coordinated
expression of AhR and Aldh1a1 could be a useful
molecular marker in melanoma.
Results
AhR levels inversely correlated with Aldh1a1 expression
in melanoma cells: AhR knockdown increased Aldh1a1
activity
We have shown that stable AhR knockdown (sh-AhR) in-
creases primary tumorigenesis and lung metastasis of
mouse melanoma cells and that AhR expression was
reduced in advanced human melanomas [23]. The in-
creased tumorigenic potential of sh-AhR melanoma cells
correlated with higher levels of cancer stem-like markers,
suggesting a more undifferentiated status [23]. On the other
hand, aldehyde dehydrogenase 1a1 (Aldh1a1) has been
recently identified as a potential melanoma promoter and a
regulator of the cancer stem cell phenotype [11–13, 24].
Here, we have investigated the contribution of Aldh1a1 to
the pro-tumorigenic effects associated to AhR deficiency.
AhR knockdown in mouse melanoma B16F10 cells signifi-
cantly increased Aldh1a1 mRNA and protein expression as
compared to wild type B16F10 cells (Fig. 1a). In contrast,
B16F10 cells expressing a constitutively active receptor
(CA-AhR) had a significant reduction in Aldh1a1 mRNA
and protein levels as compared to sh-AhR cells (Fig. 1a).
Aldh1a1 protein levels did not significantly vary between
wild type B16F10 and CA-AhR cells, regardless of their
differences in mRNA expression. Based on these results, we
next analyzed Aldh1a1 activity in our cell lines using the
Aldefluor assay. To normalize for any potential Aldh-
independent activity, determinations were done in presence
and absence of the Aldh1-specific inhibitor diethylamino-
benzaldehyde (DEAB) [8, 25]. We found that Aldh1a1
activity was significantly higher in sh-AhR than in wild type
and CA-AhR B16F10 cells, and that constitutive AhR
activation did not affect basal Aldh1a1 activity (Fig. 1b).
Aldehyde dehydrogenase activity, as measured by the
Aldefluor assay, results from the sum of various
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isoenzymes, particularly Aldh1a1 and Aldh1a3 [26]. How-
ever, since Aldh1a3 expression was not significantly differ-
ent between sh-AhR, B16F10 and CA-AhR cells
(Additional file 1: Figure S1A), we considered the differ-
ences obtained in aldehyde dehydrogenase activity as
mostly coming from Aldh1a1. To further analyze the in-
hibitory role of AhR on Aldh1a1 expression, B16F10 cells
were treated with the tryptophan metabolite and bone-fide
AhR endogenous ligand 6-formylindolo[3,2-b]carbazole
(FICZ) [27, 28]. The results showed that FICZ significantly
reduced Aldh1a1 mRNA levels in B16F10 cells (Fig. 1c).
Control experiments confirmed that FICZ was an efficient
AhR agonist in B16F10 cells as shown by the induction of
its target gene Cyp1a1 (Fig. 1d).
We then decided to analyze if Aldh1a1 was a direct tran-
scriptional target of AhR. Sequence analysis revealed that
the upstream promoter region of the mouse Aldh1a1 gene
has four xenobiotic responsive elements (XRE, 5′-GCGTG-
3′) located at positions −265, −726, −3114 and −3158 with
respect to the transcription start site. Chromatin immuno-
precipitation (ChIP) was used to detect AhR binding to
these XRE sites essentially as described [29–31]. However,
we could not demonstrate direct binding of AhR to those
XRE sites even under modified crosslinking conditions that
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Fig. 1 AhR expression represses Aldh1a1 in mouse and human melanoma cells. a B16F10-derived cell lines were previously generated to stably
express very low (sh-AhR), basal (B16F10) or a constitutively active (CA-AhR) AhR [23]. They were analyzed for Aldh1a1 mRNA expression by
RT-qPCR and for protein expression by immunoblotting. b Aldh1a1 activity was measured by flow cytometry in sh-AhR, B16F10 and CA-AhR cells
using the Aldefluor reagent kit. To normalize Aldh1a1 activity, measurements were taken in presence and absence of the Aldh1-specific inhibitor
diethylamino-benzaldehyde (DEAB). Values were then referred to those obtained for wild type B16F10 cells. c, d B16F10 cells were treated with
the AhR endogenous ligand FICZ (5 nM) and the mRNA levels of Aldh1a1 (c) and Cyp1a1 (d) determined by RT-qPCR. e A375 human melanoma
cells were transfected with a sh-AHR to downmodulate their high basal receptor levels (upper). C8161 human melanoma cells were transfected
with an AHR expression vector (AHR) to increase their low receptor levels. f, g ALDH1A1 mRNA and protein amounts were determined in A375 (f)
and C8161 (g) cell lines by RT-qPCR and immunoblotting, respectively. The expression of β-Actin was used to normalize protein loading. RT-qPCR
data were normalized by Gapdh expression and represented as 2-ΔΔCt. The B16F10 cell line was also transduced with a retrovirus containing the
empty vectors used to produce the sh-AhR and CA-AhR lines. Determinations were done in triplicate in at least two different cell cultures. Data
are shown as mean ± SD
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favour protein-DNA interactions by the addition of DSG
(disuccinimidyl glutarate) of DMA (dimethyl apidimate)
[32] (Additional file 1: Figure S1B). Thus, at present, we
cannot confirm whether or not AhR directly binds to the
mouse Aldh1a1 gene promoter.
?A3B2 tlsb=-.15pt?>The inverse correlation between
AhR and Aldh1a1 in mouse melanoma cells was also ob-
served in human melanoma cells previously reported to
express high (A375) or low (C8161) receptor levels [23].
AHR downmodulation by a sh-AHR in A375 cells
(Fig. 1e) produced a significant increase in their basal
ALDH1A1 mRNA and protein levels (Fig. 1f ). By con-
trast, AHR over-expression in C8161 cells (AHR) (Fig. 1e)
markedly reduced ALDH1A1 mRNA and protein
amounts as compared with basal C8161 cells (Fig. 1g).
Thus, AhR and Aldh1a1 had opposite expression pat-
terns in both murine and human melanoma cells.
Aldh1a1 knockdown blocked the increase in migration
and invasion produced by AhR depletion
We then hypothesized that the increased tumorigenic
and metastatic potential of sh-AhR melanoma cells [23]
could depend, at least in part, to their high Aldh1a1
activity. To analyze such possibility, we first used retro-
viral transduction to interfere Aldh1a1 expression in
B16F10 cells (sh-Aldh1a1). sh-Aldh1a1 cells had a
significant reduction in Aldh1a1 mRNA levels (Fig. 2a)
and Aldh1a1 activity (Fig. 2b) with respect to wild type
B16F10 cells. Cell counting over time and flow cytome-
try analysis of the different phases of the cell cycle
revealed that stable Aldh1a1 downmodulation did not
significantly affect cell cycle distribution (Fig. 2c) or
proliferation rates (Fig. 2d). However, wound-healing
assays revealed that Aldh1a1 interference reduced the
migration ability of B16F10 melanoma cells (Fig. 2e).
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Fig. 2 Aldh1a1 expression and activity can be downmodulated in B16F10 melanoma cells. Wild type B16F10 melanoma cells were retrovirally
transduced with a sh-RNA molecule as indicated in the Methods to produce the sh-Aldh1a1 cell line. a Aldh1a1 mRNA levels were determined in wild
type B16F10 and sh-Aldh1a1 cells by RT-qPCR. b Aldh1a1 activity was quantified by flow cytometry in both cells lines using the Aldefluor reagent kit.
c B16F10 and sh-Aldh1a1 cells were analyzed for cell cycle distribution by flow cytometry. The percentage of cells in each cell cycle phase is indicated.
d The kinetics of cell proliferation were determined by counting de number of cells during a 72 h period. e The migration of B16F10 and sh-Aldh1a1
cells was analyzed using wound healing assays. The B16F10 cell line was also transduced with a retrovirus containing the empty vectors used to
produce the sh-Aldh1a1 cell line. Measurements were done in triplicate in two different cultures. At least 6 fields were analyzed for each wound in
panel (e). Data are shown as mean ± SD. A.U. stands for arbitrary units
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As Aldh1a1 expression and activity could be manipulated
in B16F10 cells, and since we sought to investigate the
extent to which Aldh1a1 contributes to the increased
tumorigenicity caused by AhR knockdown [23], we decided
to use retroviral transduction to deplete Aldh1a1 in AhR-
interfered B16F10 cells. The cell line thus generated
(hereafter sh-AhR + sh-Aldh1a1) was used to analyze the
effects of Aldh1a1 expression in an AhR deficient back-
ground. Control experiments revealed that sh-AhR + sh-
Aldh1a1 cells had a significant reduction in both Aldh1a1
protein expression and Aldh1a1 activity as compared
to sh-AhR cells (Fig. 3a). Aldh1a1 depletion moderately
blocked the migration of sh-AhR + sh-Aldh1a1 cells in
wound healing assays with respect to Aldh1a1 expressing
sh-AhR cells (Fig. 3b). Confocal microscopy analyses of
matrigel-coated culture transwells showed that sh-AhR +
sh-Aldh1a1 cells had a significant impairment to invade
as compared to sh-AhR melanoma cells (Fig. 3c). Both
cell lines were grown at low density in 2-D cultures in
order to determine their clonogenicity potential. A quali-
tative scale was established to account for the appearance
of unexpanded (compact clones with a dense cellularity),
expanded (clones in which cells spread out and had
reduced cell-cell interactions) or intermediate clones. We
found that sh-AhR + sh-Aldh1a1 cells formed compact
clones with enhanced cell-cell interactions and with a less
invasive phenotype than that exhibited by sh-AhR cells
(Fig. 3d). Consistently, sh-AhR + sh-Aldh1a1 cells formed
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Fig. 3 Aldh1a1 knockdown reduces the migratory and invasive phenotypes produced by AhR depletion. a sh-AhR B16F10 melanoma cells were
stably transduced with a sh-RNA for Aldh1a1 to generate the sh-AhR + sh-Aldh1a1 cell line. sh-AhR and sh-AhR + sh-Aldh1a1 cells were analyzed
for Aldh1a1 protein expression by immunoblotting and for Aldh1a1 activity by flow cytometry using the Aldefluor reagent kit. To normalize
Aldh1a1 activity, measurements were taken in presence and absence of the Aldh1-specific inhibitor diethylamino-benzaldehyde (DEAB). Values
were then referred to those obtained for sh-AhR + sh-Aldh1a1 cells. b sh-AhR and sh-AhR + sh-Aldh1a1 cells were grown to confluence and then used for
wound healing migration assays. c Both cell lines were cultured in matrigel transwells and analyzed for their invasive potential by confocal microscopy. Cell
invasion at a depth of 40 μm is shown. d Clone formation in 2-D was determined by growing sh-AhR and sh-AhR + sh-Aldh1a1 cells at low cell density in
plain tissue culture dishes. Clones were counted as unexpanded (compact clones with a dense cellularity), expanded (cells spreading out with reduced
cell-cell interactions) or intermediate clones. e Clones were photographed, counted and their spreading analyzed using the ImageJ software. Three levels
of spreading were established for compact (unexpanded), intermediate and fully expanded clones. Bars correspond to 100 μm (b) and 50 μm (d). A.U.
arbitrary units. Experiments were done in duplicate or triplicate in three different cultures. At least 6 fields were analyzed for each wound in panel B. Data
are shown as mean ± SD. A.U. stands for arbitrary units
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a fewer number of fully expanded clones than sh-AhR
cells under the same culturing conditions (Fig. 3e). Thus,
the pro-migratory and pro-invasive phenotypes observed
in AhR knockdown cells may be in part dependent on
Aldh1a1 activity.
Aldh1a1 was involved in maintaining the subpopulation
of cancer stem-like cells
The tumorigenic potential of sh-AhR melanoma cells
was found to be associated with an increase in the pool
of cancer stem-like cells [23]. The effects of Aldh1a1 in
maintaining melanoma progression through the control
of cancer stem cells have been almost exclusively studied
using xenografts of human cell lines in immunodeficient
mice [11, 12, 14–16]. We next addressed whether
Aldh1a1 was required to maintain the population of
stem-like cells in our melanoma cell cultures. We first
used flow cytometry to isolate the side population (SP)
cells present in sh-AhR and sh-AhR + sh-Aldh1a1 cul-
tures based on their ability to activate the ABCG2 efflux
pump [33]. SP cells from each cell line were then further
analyzed for the expression of candidate stem cell
markers such as CD133+, whose upregulation has been
associated to increased clonogenic capacity and tumori-
genicity in melanoma [34–37]. We found that sh-AhR
+ sh-Aldh1a1 SP-cells had a significant reduction in the
number of CD133+/CD29+/CD44+ cells with respect to sh-
AhR SP-cells (Fig. 4a). Sphere formation assays under ultra-
low attachment conditions showed that sh-AhR + sh-
Aldh1a1 cells produced melanospheres of smaller size and
containing a fewer number of undifferentiated cells than
those originated from sh-AhR cells (Fig. 4b). However, the
total number of spheres generated by sh-AhR cells was not
significantly altered by Aldh1a1 depletion (Fig. 4c). mRNA
levels of differentiation related genes Sox2, Klf4, c-Myc and
Tcf4 showed no significant differences between sh-AhR and
sh-AhR + sh-Aldh1a1 cells, except for Sox2, which was
downmodulated in sh-AhR + sh-Aldh1a1 cells (Fig. 4d).
This apparent correlation between Sox2 and Aldh1a1 was
supported by the observation that ectopic Sox2 expression
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Fig. 4 Aldh1a1 downmodulation reduces cancer stem-like and pluripotency markers in AhR knockdown melanoma cells. a sh-AhR and sh-AhR +
sh-Aldh1a1 cells were stained for CD133+ (CD133-PE), CD44+ (CD44-PerCP) and CD29+ (CD29-FITC) and analyzed by flow cytometry. b, c The same
number of sh-AhR and sh-AhR + sh-Aldh1a1 cells was grown in ultra-low adherence culture dishes. The size (b) and number (c) of the melanospheres
formed were analyzed using a Cell-R microscope and the ImageJ software. d The mRNA expression levels of the pluripotency genes Sox2, Klf4, c-Myc
and Tcf4 were analyzed by RT-qPCR using total RNA isolated from sh-AhR and sh-AhR + sh-Aldh1a1 cells. e sh-AhR and sh-AhR + sh-Aldh1a1 cells were
transiently transfected with a Sox2 expression vector and the mRNA levels of Aldh1a1 quantified by RT-qPCR. The empty vector (E.V.) was
also transfected to normalize gene expression. f sh-AhR and sh-AhR + sh-Aldh1a1 cells were transfected with a Sox2 expression vector
and their migration potential determined in wound healing assays. RT-qPCR data were normalized by Gapdh expression and represented as 2-ΔΔCt.
A.U. arbitrary units. Measurements were done in triplicate in two different cultures of each cell line. At least 6 fields were analyzed for each wound in
panel (f). Data are shown as mean ± SD. A.U. stands for arbitrary units. n.s. = statistically non-significant
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increased Aldh1a1 mRNA levels in sh-AhR but not in
Aldh1a1-interfered melanoma cells (Fig. 4e), indicating
that Sox2 could play a role in maintaining Aldh1a1 ex-
pression. Moreover, Sox2 failed to rescue the migration
of Aldh1a1-depleted sh-AhR + sh-Aldh1a1 cells (Fig. 4f ),
further supporting a functional interaction between
Aldh1a1 and Sox2 in murine melanoma cells.
Aldh1a1 depletion impaired primary tumorigenesis and
lung metastasis of AhR knockdown melanoma cells
We then decided to investigate whether Aldh1a1 deple-
tion affected primary tumorigenesis and metastasis of
AhR knockdown B16F10 cells. We first examined if
single Aldh1a1 knockdown affected tumor formation in
AhR expressing cells. To do that, B16F10 wild type and
sh-Aldh1a1 cells were inoculated in either dorsal flank
of AhR+/+ immunocompetent mice. Tumor analysis
revealed that sh-Aldh1a1 cells produced tumors of
similar weight (Fig. 5a) and volume (Fig. 5b) than those
originated from wild type B16F10 cells, indicating that,
at least in our experimental conditions using immuno-
competent recipient mice, Aldh1a1 depletion alone was
not enough to affect melanoma primary tumorigenesis.
We next performed similar experiments injecting sh-AhR
and sh-AhR + sh-Aldh1a1 cells in either dorsal flank of
AhR+/+ immunocompetent mice. AhR +Aldh1a1 deple-
tion produced tumors of significantly smaller weight
(Fig. 5c) and volume (Fig. 5d) than those generated by
Aldh1a1-expressing sh-AhR cells. When injected through
the tail vein, sh-AhR + sh-Aldh1a1 cells exhibited a close
to three fold reduction in their metastatic potential to the
lungs as compared to sh-AhR cells (Fig. 5e).
To further analyze the effects of Aldh1a1 in the meta-
static burden of melanoma cells, we used retroviral
transduction to produce sh-AhR-Luc and sh-AhR + sh-
Aldh1a1-Luc cells expressing the in vivo marker
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Fig. 5 Aldh1a1 knockdown blocks primary tumorigenesis and lung metastasis induced by AhR depletion. a, b B16F10 and sh-Aldh1a1 cells were
injected subcutaneously in the dorsal flank of AhR+/+ immunocompetent mice. Each cell line was injected in one of the two flanks of each
mouse. Tumors were collected, weighted (a) and their volume (b) calculated using the formula [length x width2 x 0.4]. A total of 9 and 8 tumors
were analyzed for B16F10 and sh-Aldh1a1 cells, respectively. c, d sh-AhR and sh-AhR + sh-Aldh1a1 cells were injected subcutaneously in the dorsal
flank of AhR+/+ immunocompetent mice. Each cell line was injected in one of the two flanks of each mouse. Tumors were collected, weighted
(c) and their volume (d) calculated using the formula [length × width2 × 0.4]. A total of 12 and 14 tumors were analyzed for sh-AhR and sh-AhR +
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shown as mean ± SD. n.s. = statistically non-significant
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luciferase. In vivo imaging analyses (IVIS) revealed that
metastatic dissemination started 11 days after inoculation
for both cell lines (Fig. 6a). At later times (e.g., 21 days),
total metastatic load was reduced in sh-AhR + sh-Aldh1a1
cells with respect to sh-AhR cells (Fig. 6b). Metastatic
dissemination correlated to a certain degree with mice
survival, which was moderately extended in mice receiving
sh-AhR + sh-Aldh1a1 cells (Fig. 6c). These results sug-
gested that Aldh1a1 is a likely intermediate in the tumor
promoting effects caused by AhR depletion.
Aldh1a1 knockdown in sh-AhR + sh-Aldh1a1 cells pro-
duced melanospheres and tumors of significantly smaller
size than those arising from sh-AhR cells. Such diminished
tumorigenicity could be due to a reduction in the number
of cancer stem-like cells present in sh-AhR + sh-Aldh1a1
cultures and/or to a less undifferentiated status. To address
this question, we used flow cytometry-assisted cell sorting
to isolate viable CD133+ cells from the SP subpopulations
of sh-AhR and sh-AhR + sh-Aldh1a1 cultures. The same
number of CD133+ cells from each cell line was then sub-
cutaneously injected into either flank of AhR+/+ immuno-
competent recipient mice. We found that tumors formed
by sh-AhR + sh-Aldh1a1 CD133+ cells were similar in
weight (Fig. 7a) and volume (Fig. 7b) than those produced
by sh-AhR CD133+ cells, suggesting that a reduction in the
number of cancer stem-like cells could be the most likely
factor compromising tumor growth by Aldh1a1 depleted
AhR + sh-Aldh1a1 cells.
Discussion
Defining the mechanisms and the molecular intermedi-
ates that regulate growth and metastatic dissemination
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Fig. 6 Reduced Aldh1a1 expression blocks the metastatic burden of AhR depletion in melanoma cells. a sh-AhR:LUX and sh-AhR + sh-Aldh1a1:LUX cells,
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of tumor cells represents a major topic in cancer. We
have previously reported that stable AhR knockdown
increased the tumorigenic and metastatic abilities of
B16F10 melanoma cells, suggesting that this receptor
could have a tumor suppressor role in melanoma. Inter-
estingly, the increased tumorigenicity of sh-AhR cells
appeared to be associated to the accumulation of cancer
stem-like cells [23]. In this work, we have investigated
the Aldh1a1 enzyme as a molecular intermediate whose
upregulation in AhR depleted cells could promote mel-
anoma progression. The main findings from this study
are that AhR expression restrains Aldh1a1 activity in
murine melanoma cells and that, as a consequence, AhR
depletion results in Aldh1a1 upregulation and in the
exacerbation of melanoma primary tumorigenesis and
metastasis in vivo. In agreement with these findings,
stable Aldh1a1 knockdown was able to block the effects
induced by AhR deficiency both in vitro and in vivo. We
therefore suggest that AhR may block melanoma by
inhibiting the pro-tumoral effects of Aldh1a1, and that
coordinated expression of AhR and Aldh1a1 could be a
useful molecular marker in melanoma.
It is generally accepted that Aldh1a1 is a pro-tumoral
enzyme associated to poor prognosis in several cancer
types. Aldh1a1 appears to have a causal role in maintaining
the undifferentiated status of breast [10, 38], lung [39] and
prostate [40] tumors and of soft tissue sarcomas [8],
carcinomas [9, 41] and melanoma. Regarding melanoma,
this enzyme has been suggested as a marker to identify
subpopulations of cancer stem cells [11, 12]. We, and
others, have also established an association between AhR
and melanoma. AhR mediates growth inhibition of melan-
oma cells by the therapeutic drug leflunomide [42], whereas
constitutive AhR activation repressed melanoma growth
and metastasis [23]. The results presented here, propose
the existence of regulatory pathway between AhR and
Aldh1a1 in melanoma considering that the pro-
tumorigenic effects of Aldh1a1 overexpression were signifi-
cantly augmented in an AhR deficient background. The fact
that a constitutively active AhR or a bona-fide endogenous
ligand could repress Aldh1a1 gives additional support to
such pathway and suggests that non-toxic AhR ligands
could inhibit the progression of melanomas having high
levels of Aldh1a1 activity. Although our results strongly
support that AhR modulates Aldh1a1 mRNA expression in
murine melanoma cells, it is still undefined whether it
requires AhR binding to the XRE elements present in the
Aldh1a1 promoter. The lack of AhR binding in chromatin
immunoprecipitation assays would suggest an indirect
mechanism involving additional intermediates or, alterna-
tively, a failure of the available reagents to detect the
specific AhR-DNA complexes organized at those XRE sites.
AhR has been shown to regulate xenobiotic-unrelated
genes by direct promoter binding (Vav3 oncogene [29]) or
by indirect mechanisms involving changes in histone
acetylation (latent TGFβ binding protein Ltbp1 [32]).
Aldh1a1 downmodulation reduced melanoma cell mi-
gration and invasion in vitro and tumor growth and
metastatic dissemination in vivo. However, these effects
were only seen in cells simultaneously depleted of AhR
expression. Thus, it seems that Aldh1a1 knockdown
impairs the cell-autonomous potential of AhR-depleted
cells to develop larger and more metastatic lesions. Since
AhR negatively modulate Aldh1a1 activity, melanoma
tumors could restrict AhR expression in order to main-
tain the tumor promoting activity of Aldh1a1. In this
context, the inverse correlation observed between AhR
and Aldh1a1 could gain additional interest considering
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that AhR protein levels were reduced in high grade human
melanomas as compared to non-malignant nevi [23]. We
have attempted to determine Aldh1a1 levels by immuno-
histochemistry in our tissue microarrays (TMA) containing
human melanomas expressing different amounts of AHR
[23]. However, the antibodies to detect human ALDH1A1
commercially available do not give enough sensitivity and
specificity to correlate ALDH1A1 and AHR in such tissue
sections. The development of clinically validated reagents
could help solve this limitation.
Aldh1a1 and AhR converge at the control of the
cancer stem-like phenotype in melanoma cells, although
with an opposite pattern that resembles that found for
tumor growth. High Aldh1a1 expression is being consid-
ered not only a marker [43, 44] but also a potential tool
to isolate stem-like cells in melanoma [11–13]. Regard-
ing AhR, its repression favours the growth of human
hematopoietic stem cells [45], the development of mouse
embryonic stem cells [46], the acquisition of an EMT
phenotype in epithelial cells [21] and the expansion of
stem-like cells in melanoma [23]. Consistent with such
opposing functions of these two proteins in tumor
development, our results suggest that the enhanced
tumoral response produced by AhR deficient cells could
be at least partially due to their increased content in
cancer stem-like cells perhaps as a consequence of
Aldh1a1 overactivation. Indeed, Aldh1a1 downmodulation
markedly reduced the number of cancer stem-like cells and
impaired primary tumorigenesis and lung metastasis in
AhR depleted melanoma cells. Among the molecules that
could mediate the pro-tumoral effects of Aldh1a1, the stem
cell regulator Sox2 appears as a plausible candidate. The
evidences showing that Sox2 expression was coincident
with Aldh1a1 overactivation, and that Sox2 expression
inhibited Aldh1a1 in AhR knockdown cells, suggest the ex-
istence of a coordinated pathway involving AhR-Aldh1a1-
Sox2 in the regulation of stemness in melanoma cells. In
agreement with such possibility, recent studies have shown
that high Aldh1a1 and Sox2 expression correlates with an
undifferentiated and metastatic phenotype in oral squa-
mous cell carcinomas [41] and that Sox2 depletion blocks
the tumor-initiating ability of human melanoma cells ex-
pressing high levels of Aldh1a1 [14].
The functional interaction between Aldh1a1 and AhR
could be also relevant for the control of migration and
invasion of melanoma cells. Previous studies have shown
that epithelial cells lacking AhR migrate faster in vitro
and in vivo [47] and that AhR downmodulation induces an
epithelial-to-mesenchymal transition eventually resulting in
enhanced cell invasion [21]. Notably, siRNA-mediated
transient silencing of ALDH1A1 inhibited cell migration in
human H2087 non-small cell lung cancer cells [48] and
invasion in A498 human renal carcinoma cells [49].
Although the mechanisms by which the AhR-Aldh1a1 axis
participates in the control of cell migration and invasion
remain largely unknown, they may involve cell-cell and
cell-substratum signalling since recent work has shown that
AhR regulates cytoskeleton organization and the dynamics
of focal adhesions [47, 50, 51], β1 integrin activation [52]
and caveolin-1 dependent signalling [53].
Conclusions
In summary, we present evidences for the existence of a
regulatory mechanism by which AhR modulates Aldh1a1
expression and activity in melanoma cells. In an AhR
deficient background, increased Aldh1a1 activity likely
supports primary tumorigenesis and lung metastasis of
melanoma cells, whereas a reduction in Aldh1a1 activity
impaired the pro-tumorigenic effects caused by AhR
depletion. Since AhR expression appears to be reduced
in advanced human melanomas, it will be interesting to
investigate whether Aldh1a1 becomes upregulated in the
same tumors and if it contributes to disease progression.
It can be speculated that AhR activation by endogenous
non-toxic ligands could repress Aldh1a1 expression
blocking tumor growth. Therefore, the functional inter-
action between AhR and Aldh1a1 could be of potential
interest for melanoma progression and therapy.
Methods
Cell lines and mice
B16F10 mouse melanoma cells were from the American
Type Culture Collection (ATCC). Human melanoma
C8161 and A375 cell lines were authenticated by DNA pro-
filing using 8 different and highly polymorphic short
tandem repeat (STR) loci (German Biological Resource
Centre DSMZ). B16F10 cells were also analyzed for their
melanin production. All melanoma cells were cultured in
DMEM containing 10 % FBS, 100 U/ml penicillin, 100 μg/
ml streptomycin and 2 mM L-glutamine at 37 °C and 5 %
CO2 atmosphere. For primary tumorigenesis and lung me-
tastasis experiments, wild type immunocompetent AhR+/+
mice [54] at 8–10 weeks of age were inoculated with genet-
ically modified B16F10 melanoma cells as indicated below.
To analyze systemic metastatic dissemination, genetically
modified B16F10 melanoma cells were injected into albino
C57BL6 mice (Harlan). All the experiments involving mice
were approved by the Bioethics and Biosecurity Commis-
sions of the University of Extremadura and the Instituto de
Parasitología y Biomedicina López Neyra (IPBLN, CSIC)
within the approved project BFU-2011-22678 and under
the approved protocol 11/2011. Mice had free access to
water and rodent chow.
Antibodies, vectors and reagents
The affinity purified AhR antibody (SA-210) was from
Enzo, CD133-PE, CD44-PerCP and CD29-FITC were from
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Biolegend. Antibodies for Aldh1a1 were from Becton-
Dickinson and Santa Cruz Biotechnology. The antibody for
β-actin was obtained from Sigma-Aldrich. Matrigel-coated
transwells were from Becton-Dickinson. The iScript™ Re-
verse Transcription Supermix was from Bio-Rad and the
SYBR® Select Master Mix for real-time PCR from Life
Technologies. The AhR agonist 6-formylindolo[3,2-b]car-
bazole (FICZ) was from Enzo and it was used at a 5 nM
concentration.
Retroviral transduction
B16F10 melanoma cells were stably transduced with retro-
viruses containing small hairpin RNAs for AhR (sh-AhR),
Aldh1a1 (sh-Aldh1a1) or AhR +Aldh1a1 (sh-AhR + sh-
Aldh1a1) essentially as described [21, 23]. To produce the
sh-AhR + sh-Aldh1a1 cell line, B16F10 sh-AhR cells [23]
were infected with an sh-Aldh1a1-containing retrovirus.
Knockdown of Aldh1a1 was determined by real time RT-
qPCR and Western blotting and by flow cytometry using
the Aldefluor reagent kit as described below. In certain
experiments, a B16F10 cell line engineered to express a
constitutively active receptor [23] was also used. The
human A375 melanoma cell line was also transduced with
a retrovirus containing a human sh-AhR (A375 sh-AhR)
as previously indicated [23]. The sh-RNA sequence for
AhR was: 5′TGCTGTTGACAGTGAGCGCTCAGTGTA
TCTTGTAAAGAAATAGTGAAGCCACAGATGTATT
TCTTTACAAGATACACTGAATGCCTACTGCCTCG
GA3′. The sh-RNA sequence for Aldh1a1 was: 5′TG
CTGTTGACAGTGAGCGCAGATGCCAGGTGAAGA
GCCGTTAGTGAAGCCACAGATGTATCGGCTCTT
CTCCTGGCTTCTTTGCCTACTGCCTCGGA3′.
Transient transfection
Transient transfections were done in human C8161 and
mouse B16F10 melanoma cells. Briefly, 2×105 cells were
cultured in 35 mm dishes for 24 h. Then, cells were
transfected with 1 μg of the expression vectors pBA-
BE:AhR (C8161) or pBABE:Sox2 (B16F10) using the
TurboFect reagent (Fermentas) as indicated by the
manufacturer. Transfections were performed in Opti-
MEM® I Reduced Serum Medium (Life Technologies).
Experiments were done 24 h after transfection.
SDS-PAGE and immunoblotting
SDS-PAGE and immunoblotting were performed using
total protein extracts from A375, C8161, sh-AhR and
sh-AhR + sh-Aldh1a1 cells as previously described [55].
Reverse transcription and real-time PCR
Total RNA was isolated using the High Pure RNA Isola-
tion Kit (Roche). Reverse transcription was performed
using random priming and the iScript Reverse Tran-
scription Super Mix (Bio-Rad). Real-time PCR was used
to quantify the mRNA levels of Aldh1a1, Sox2, Tcf4, c-
Myc, Klf4 and Cyp1a1. Reactions were done using SYBR®
Select Master Mix (Life Technologies) in a Step One
Thermal Cycler (Applied Biosystems) essentially as de-
scribed [52]. Gapdh was used to normalize gene expres-
sion (ΔCt) and 2-ΔΔCt to calculate changes in mRNA
levels with respect to control or untreated conditions.
The following primer sequences were used to analyze
murine genes: Aldh1a1 5′-CTCCTGGCGTGGTAAAC
ATT-3′ (forward) and 5′-CCATGGTGTGCAAACTC
AAC-3′ (reverse); Aldh1a3 5′-ATCAAACCCACGGTC
TTCTC-3′ (forward) and 5′-TTTGTCCAGGTTTTTG
GTGA-3′ (reverse); Sox2 5′-CACAACTCGGAGATCA
GCAA-3′ (forward) and 5′-CCGGGAAGCGTGTACTT
ATC-3′ (reverse); Tcf4 5′-CTTCTTTGGCGAGTGGA
CA-3′(forward) and 5′-GTGACCCAAGATCCCTGCT-
3′ (reverse); Klf4 5′-CACAAGTCCCCTCTCTCCAT-3′
(forward) and 5′-TTTCTCGCCTGTGTGAGTTC-3′
(reverse); c-Myc 5′-CCTGACGACGAGACCTTCA-3′
(forward) and 5′-TGGTAGGAGGCCAGCTTCT-3′ (re-
verse); Cyp1a1 5′-ACAGACAGCCTCATTGAGCA-3′
(forward) and 5′-GGCTCCACGAGATAGCAGTT-3′
(reverse); Gapdh 5′-TGAAGCAGGCATCTGAGGG-3′
(forward) and 5′-CGAAGGTGGAAGAGTGGGAG-3′
(reverse). For human genes, the following primers were
used: ALDH1A1 5′-AAACGGAGGCCAGGATAACT-3′
(forward) and 5′-CCATGGTGTGCAAACTCAAC-3′
(reverse); GAPDH 5-CCACCCAGAAGACTGTGGAT-
3′ (forward) and 5′-TTCTAGACGGCAGGTCAGGT-
3′ (reverse).
Chromatin Immunoprecipitation (ChIP)
Chromatin immunoprecipitation (ChIP) was performed
essentially as described [30–32]. In brief, protein-DNA
complexes were crosslinked by formaldehyde treatment
and sonicated for 20 min in a Bioruptor (Dianogenode)
apparatus. Following centrifugation, the sonicated DNAs
were first preincubated with protein A/G agarose beads to
reduce unspecific binding and then immunoprecipitated
overnight at 4 °C with 4 μg of anti-AhR antibody in
presence of fresh protein A/G agarose beads. DNAs were
eluted from the immunoprecipitates, extracted and ethanol
precipitated. PCR for murine Aldh1a1 gene promoter
regions containing potentially active AhR binding sites was
performed using the oligonucleotides: Aldh1a1-proximal
5′-CCTTTGTTCCGGAGTCTGTT-3′ (forward) and 5′-
TTTACCAAGCCAAACCTGTG-3 (reverse); Aldh1a1-dis-
tal 5′-ATGGCTCATTGGCTAATCGT-3′ (forward) and
5′-GTGCAAGTGTGAGAGGAAGG-3′ (reverse). Diluted
samples of total DNA were amplified as the input fractions.
Negative controls were done in the absence of specific anti-
body. The amplified DNA was separated on 2.5 % agarose
gels and visualized by ethidium bromide staining.
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Cell proliferation and cell cycle analyses
Cell proliferation was determined by quantifying the
increase in cell numbers over time (up to 72 h) in B16F10
and sh-Aldh1a1 cell cultures. The number of cells attached
to the plates was obtained after tripsinization and counting
in a TC-10 automated cell counter (Bio-Rad). Flow cytome-
try was used to analyze cell cycle distribution. Cells were
trypsinized, washed in PBS, fixed at 4 °C in 70 % cold
ethanol and treated with RNase (10 mg/ml) for 30 min at
37 °C. DNA content per cell was determined in a Cytomics
FC500 flow cytometer after staining with propidium iodide
(50 μg/ml) for 15 min at RT in the dark. For cell cycle
analysis, only signals from single cells were considered
(10.000 cells/sample).
Aldh1a1 activity
Aldh1a1 activity was measured using the Aldefluor reagent
kit (StemCell Technologies) following the instructions of
the manufacturer. In brief, cells were incubated for 60 min
at 37 °C with the Aldefluor reagent in absence or presence
of the Aldh1 inhibitor diethylamino-benzaldehyde (DEAB).
After incubation, aliquots of 104 cells were analyzed for
Aldh1a1 activity in a Cytomics FC500 cytometer (Beckman
Coulter). Non-viable cells were excluded from the analysis
by propidium iodide staining. Enzymatic activity was nor-
malized with respect to that measured in DEAB-treated
cells.
Clone formation
Clone formation was analyzed by platting 5×102 or 103
sh-AhR or sh-AhR + sh-Aldh1a1 cells in plain culture
dishes for 5 days. Then, clones were gently washed in PBS
and stained for 10 min with 0.5 % (w/v) crystal violet.
Clones were counted and analyzed for cell spreading using
the ImageJ software (version 1.45S). A qualitative scale
was established to account for the appearance of unex-
panded (compact clones with a dense cellularity), ex-
panded (clones in which cells spread out and had reduced
cell-cell interactions) or intermediate clones.
Cell migration and invasion
Cell migration was analyzed in a Cell-R fluorescence
microscope (Olympus, Tokyo, Japan) using 2-D wound
healing assays as reported [21, 23]. The ability of B16F10
cell lines to invade through matrigel-coated transwells
was determined using an Olympus FV1000 confocal
microscope as described [56].
Melanosphere formation
sh-AhR and sh-AhR + sh-Aldh1a1 cells were grown at
3×104 cells/well in ultra-low adherence 24-well plates
(Nunc, Thermo Fisher). After 24 h, melanospheres formed
were analyzed with an Olympus Cell-R microscope. Sphere
number and size were quantified using the ImageJ software
(version 1.45S).
Flow cytometry of side population (SP) and CD+ cells
Side population cells (SP) present in sh-AhR and sh-
AhR + sh-Aldh1a1 cultures were first analyzed using
published criteria [57] in a MoFlo-XDP equipment
(Beckman-Coulter). To isolate SP cells, cultures were
stained with 5 μg/ml Hoechst 33342 (Sigma-Aldrich) for
90 min at 37 °C, centrifuged and resuspended in HEPES-
HBSS buffer containing 2 % FBS. Aliquots of cells were
treated with 50 μM of the ABCG2 extrusion pump inhibi-
tor fumitremorgin C (Sigma-Aldrich). Propidium iodide
(10 nM) was used to discriminate dead cells. To quantify
SP subpopulations, Hoechst 33342-labeled cells were
stained for CD133+ (CD133-PE), CD44+ (CD44-PerCP)
and CD29+ (CD29-FITC) during 30 min at 10 °C. To-Pro
(0.1 μM) was used to discriminate dead cells from the
analyses.
Melanoma primary tumorigenesis and lung metastasis
Aliquots of 105 exponentially growing sh-AhR and sh-
AhR + sh-Aldh1a1 cells were injected subcutaneously in
either flank of AhR+/+ immunocompetent recipient mice
and tumors allowed to grow for 15 days. Mice were killed
and tumors recovered, weighted and measured with a cali-
per. Tumor volume was calculated using the formula:
[length × width2 × 0.4]. For lung metastasis assays, 105
cells were resuspended in 100 μl PBS and injected through
the tail vein of AhR+/+ immunocompetent recipient mice.
After 21 days, mice were killed and their lungs extracted
and analyzed for the presence of melanoma-derived meta-
static nodules.
In vivo imaging (IVIS)
The metastatic potential of sh-AhR and sh-AhR + sh-
Aldh1a1 melanoma cells was also analyzed in vivo using
the IVIS imaging system. Cells were further engineered
to stably express the luciferase gene (LMP:sh-AhR:LUX
and LMP:shAhR + shAldh1a1:LUX). C57BL6 albino mice
at 8 weeks of age were injected through the tail vein
with 106 sh-AhR:LUC or sh-AhR + sh-Aldh1a1:LUC cells
in 50 μl DMEM medium. Mice were analyzed for meta-
static dissemination at the time of injection (0 days) and
after 2, 7, 11, 14 and 21 days. At each time point, mice
were anesthetized with isofluorane and injected i.p. with
30 mg firefly luciferin in 100 μl PBS. Mice were then
quickly introduced into the IVIS equipment (Xenogen)
and images collected in dorsal and ventral positions. At
day 21, mice were killed and their organs photographed
and fixed in buffered formalin for further analyses. The
emission of luminescence was quantified as photons per
second using the Living Image software (Xenogen).
Contador-Troca et al. Molecular Cancer  (2015) 14:148 Page 12 of 14
Statistical analyses
Data are shown as mean ± SD. Comparisons between
experimental conditions was done using GraphPad
Prism 6.0 software (GraphPad). The student’s t test was
used to analyze differences between two experimental
groups and ANOVA for the analyses of three or more
groups. The Mann–Whitney non-parametric statistical
method was used to compare rank variations between
independent groups. Experiments were done in duplicate
or triplicate in at least three cultures of each cell line.
Additional file
Additional file 1: Figure S1. (A) AhR expression does not significantly
affect Aldh1a3 mRNA levels. Wild-type B16F10, sh-AhR and CA-AhR
melanoma cells were analyzed for Aldh1a3 expression by RT-qPCR using
total RNA and specific oligonucleotides. RT-qPCR data were normalized
by Gapdh expression and represented as 2-ΔΔCt. (B) AhR does not bind
the murine Aldh1a1 gene promoter under our experimental conditions.
The same cell lines were analyzed for AhR binding to the murine Aldh1a1
promoter by chromatin immunoprecipitation assays (ChIP) using the
affinity purified AhR antibody (SA-210) (AhR Ab). A representative
experiment for the proximal XRE sites is shown. Similar results were
obtained for the distal XRE sites (see the Methods). Positive and negative
controls include total DNA input (Input) and immunoprecipitations
performed in presence of IgG, respectively. Determinations were done in
duplicate in two different cell cultures. Data are shown as mean ± SE.
(PPTX 941 kb)
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